The letter from your ophthalmologist said your retina was stable. You’ve been on semaglutide for four months. Then, last Tuesday, something changed – a grey curtain appeared at the edge of your vision. You waited two days to see if it would resolve.<\/p>\n\n\n\n
That was the wrong call.<\/p>\n\n\n\n
Some visual changes on GLP-1 therapy are expected and benign. Some are emergencies. The problem is they can look similar from the inside. This guide draws the line clearly.<\/p>\n\n\n\n
GLP-1 medications work by changing how your body manages glucose and appetite. What most patients don’t expect is that some of these effects touch the eye.<\/p>\n\n\n\n
Two mechanisms are most relevant. First, rapid glucose lowering in people with existing diabetic eye disease can temporarily worsen retinopathy – the blood vessels in the retina, accustomed to years of high glucose, can react adversely when glucose drops quickly.[1] This is called “early worsening” of diabetic retinopathy and is documented in clinical trial data for semaglutide.<\/p>\n\n\n\n
Second, there is a separate and debated association between GLP-1 use and non-arteritic anterior ischaemic optic neuropathy (NAION) – a condition where blood supply to the optic nerve is temporarily interrupted. The evidence for this link is still under investigation; a large 2024 pharmacovigilance study raised the concern, while subsequent analyses have produced mixed results.[2] What matters clinically is that NAION presents with sudden, painless vision loss – and it is an emergency.<\/p>\n\n\n\n
Understanding which changes fall under which category is the purpose of this guide.<\/p>\n\n\n\n
These changes require immediate care – not a call to your family doctor, not an appointment tomorrow:<\/p>\n\n\n\n
These presentations can indicate NAION, retinal artery occlusion, or vitreous haemorrhage. Time to treatment matters. Do not drive yourself.<\/p>\n\n\n\n
These changes are not immediately catastrophic but should not wait:<\/p>\n\n\n\n
Sudden new floaters with flashes can indicate a posterior vitreous detachment, which in some cases progresses to retinal tear. Same-day evaluation is warranted.<\/p>\n\n\n\n
These warrant evaluation but are not emergencies:<\/p>\n\n\n\n
Inform your prescribing doctor and get a baseline ophthalmology check if you haven’t had one in the past year.<\/p>\n\n\n\n
Not everything that changes is worrying:<\/p>\n\n\n\n
Track these in writing. Mention them at your next scheduled appointment. Do not ignore them – but do not escalate to the emergency department.<\/p>\n\n\n\n
Whether you go to the ER or call a clinic, the information you communicate in the first 60 seconds matters.<\/p>\n\n\n\n
Say this clearly:<\/p>\n\n\n\n
“I am on semaglutide [or tirzepatide \/ Ozempic \/ Wegovy \/ Mounjaro \/ Zepbound]. I have been on it for [X months]. My dose was last changed [X weeks ago]. My vision changed [describe exactly: which eye, what you see, when it started, how fast it changed].”<\/em><\/p>\n\n\n\n This helps the clinician immediately consider GLP-1 related mechanisms. Many emergency physicians will not ask about GLP-1 use spontaneously.<\/p>\n\n\n\n Also note: whether you have diabetes and any known diabetic retinopathy status. If you have retinal imaging reports, bring them or note where they are.<\/p>\n\n\n\n Not everyone on GLP-1 therapy has the same eye risk profile. Your risk of vision-related complications is meaningfully higher if you have:<\/p>\n\n\n\n If any of these apply, discuss ophthalmology monitoring with your prescribing doctor before reaching the point where vision changes prompt a call. Proactive retinal imaging at treatment initiation is appropriate in this group.[4]<\/p>\n\n\n\n The NAION-GLP-1 association generated significant attention following a 2024 case series at a neuro-ophthalmology referral centre. That study was not population-level, which means it captured severe cases selectively. Population-level pharmacovigilance studies have produced conflicting risk estimates.[2]<\/p>\n\n\n\n What this means in practice: the association is plausible given GLP-1 vascular effects, and the absolute risk remains low. In June 2025, the European Medicines Agency concluded a formal safety review and classified NAION as a “very rare” side effect of semaglutide medicines, estimated at up to 1 in 10,000 patients treated, and the World Health Organization issued a corresponding alert to clinicians.[5] The US FDA has not yet updated semaglutide product labelling to include NAION, though the signal remains under active review there as well.<\/p>\n\n\n\n For patients: this does not mean the risk is zero. It means you should know what sudden vision loss looks like and not wait.<\/p>\n\n\n\n For prescribers: this means baseline ophthalmologic status in at-risk patients is clinically reasonable even absent a formal guideline.<\/p>\n\n\n\n This article is for educational purposes only and does not constitute medical advice. If you experience sudden vision loss or any of the Category 1 symptoms described above, seek emergency care immediately. Educational content about GLP-1 medications and eye health should not replace evaluation by a qualified ophthalmologist or emergency physician.<\/em><\/p>\n\n\n\n Vision changes can be hard to describe under pressure. Tracking exactly what you noticed, when, and how fast it changed, before you walk into a clinic, helps every clinician you speak to.<\/p>\n\n\n\n Join the Field Notes for tools designed for people managing their health with GLP-1 medications, including symptom tracking guidance and appointment preparation checklists.<\/p>\n\n\n\n
\n\n\n\nWho Has Higher Background Risk<\/h2>\n\n\n\n
\n
\n\n\n\nEvidence Gaps and What Is Still Uncertain<\/h2>\n\n\n\n
\n\n\n\n
\n\n\n\nTrack Your Symptoms and Questions Before Your Appointment<\/h2>\n\n\n\n
\n\n\n\nREFERENCES<\/h2>\n\n\n\n